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Problem: Crry is a widely expressed type 1 transmembrane complement regulatory
protein in rodents which protects self-tissue by downregulating C3 activation. Crry−/−
concepti produced by Crry+/− × Crry+/− matings are attacked by maternal complement
system leading to loss before day 10. The membrane attack complex is not the mediator of this death. We hypothesized that the ability of C3b to engage the alternative
pathway’s feedback loop relatively unchecked on placental membranes induces the
lesion yielding the demise of the Crry−/− mouse.
Method of Study: We investigated the basis of Crry−/− conceptus demise by depleting
maternal complement with cobra venom factor and blocking antibodies. We monitored their effects primarily by genotyping and histologic analyses.
Results: We narrowed the critical period of the complement effect from 6.5 to
8.5 days post-coitus (dpc), which is immediately after the conceptus is exposed to
maternal blood. Deposition by 5.5 dpc of maternal C3b on the placental vasculature
lacking Crry−/− yielded loss of the conceptus by 8.5 dpc. Fusion of the allantois to the
chorion during placental assembly did not occur, fetal vessels originating in the allantois did not infiltrate the chorioallantoic placenta, the chorionic plate failed to develop, and the labyrinthine component of the placenta did not mature.
Conclusion: Our data are most consistent with the deposition of C3b being responsible for the failure of the allantois to fuse to the chorion leading to subsequent conceptus demise.
KEYWORDS

alternative pathway, C3b deposition, complement membrane regulatory activity deficiency,
complement system, conceptus demise, Crry, fusion of the allantois to the chorion

1 | I NTRO D U C TI O N

clearance by phagocytic cells, promote inflammation, and perturb
cell surfaces via the membrane attack complex (MAC; C5b-9).

The alternative pathway (AP) of the complement system is vital to

Regulation of convertase activity is required to maintain homeo-

host defense against pathogens yet also contributes to autoimmune

stasis and protect self-
tissue. Membrane cofactor protein (MCP;

and inflammatory diseases. In host defense, the effects of comple-

CD46) and decay accelerating factor (DAF; CD55) are proteins ex-

ment activation are largely dependent on the cleavage of C3 by the

pressed on most healthy cells that regulate convertases. Factor H

C3 convertases, enzyme complexes assembled during complement

(FH) is an abundant plasma protein that prevents formation of and

activation (Figure 1A). C3 cleavage products opsonize targets for

dissociates convertases via decay accelerating activity and cofactor
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activity (Figure 1B). Absence of these normal regulators of the AP
are the cause of a number of human diseases, including atypical he-
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2.2 | Timed matings and harvesting embryos

molytic uremic syndrome (aHUS),1-6 C3 glomerulopathies (C3GN),1-6

After female mice were placed in the male’s cage, each subse-

age-
related macular degeneration (AMD),7-11 and protein-
losing

quent day the female was checked for a vaginal plug. The day of

enteropathy.12

plug observance was assigned 0.5 dpc. Mice were expected to de-

Crry is a widely expressed type 1 transmembrane protein in ro-

liver at 19.5 dpc. Pregnant mice were sacrificed by CO2 asphyxia-

dents that downregulates the AP. It has strong cofactor activity for

tion in accordance with institutional guidelines. The uterus was then

C3b and moderate decay accelerating activity for the classical path-

removed and each implantation site was separated surgically. The

way.13-15 Crry’s broad expression profile and regulatory activities

muscular uterus was removed under a dissecting microscope while

are similar to membrane cofactor protein (MCP/CD46) in primates

the implantation site was placed in cold PBS. Pregnant mice were

(Figure 1B).16 MCP has a limited expression profile in rodents, being
present primarily on the inner acrosomal membrane of spermatozoa.9,16-18 Crry−/− concepti produced by Crry+/− × Crry+/− matings
are attacked by the maternal AP leading to loss before 10 days.15
Notably, Crry−/− pups can be rescued if the mother is deficient in any
1 of the 4 components (C3, FB, FD, and properdin) of the AP (13-15
and X. Wu and J.P. Atkinson, unpublished). Fetal loss that occurs
is not dependent on antibody (μMT−/− background) or the classical
or lectin pathway of complement (C4−/− background).13 Moreover,
demise is not mediated by the MAC, as the C6-deficient mouse conceptus does not rescue the demise phenotype.19 However, C5a may
play a minor role: C5−/− background led to ~5% of offspring being
Crry−/− although much less than the expected 25% of offspring.13
These results indicate that fetal loss occurs primarily through AP-
directed events, prior to formation of the C5 convertase and the
membrane attack complex.
Herein, we test the hypothesis that the ability of C3b to engage the AP feedback loop in the absence of proper membrane
regulation induces the placental lesion yielding the demise of the
Crry−/− mouse. Specifically, we surmise that a reduction in maternal AP activity at ~6.5 days post-coitus (dpc) would prevent conceptus demise. The mouse blastocyst enters the uterus at 4.5 dpc
yet the conceptus is not directly exposed to maternal blood until
5.0-6 .5 dpc. 20 As early as 6.5 but completely by 7.5 dpc, the ectoplacental cone cells that will evolve into the chorioallantoic placenta are bathed in maternal blood, thereby exposing to proteins
of the complement cascade. Neutrophil depletion and C3a receptor blockade failed to rescue the conceptus. Overall, the results
further suggest that C3b deposition is responsible for the loss of
the conceptus.13-15,19

2 | M ATE R I A L S A N D M E TH O DS
2.1 | Mouse breeding and genotyping
Mice were bred and maintained under pathogen-free conditions at
Washington University School of Medicine (WUSM) in St. Louis,
MO in accordance with institutional animal care guidelines. The
Crry knockout mouse was originally generated by Molina and colleagues14 and has been maintained at WUSM. The Crry−/− allele was
genotyped by PCR as described.15 The C3aR knockout mouse was a
gift from Richard Wetsel (University of Texas, Houston) and genotyped by PCR.

F I G U R E 1 Alternative pathway of complement activation:
feedback loop and regulation by cofactor activity. A, Four
plasma proteins, C3, factor B (FB), factor D (FD), and properdin
(P) assemble into the AP C3 convertase. C3 convertase has a
continuous activity that generates a basal level of C3b. C3b
engages the zymogen Factor B (FB) that is then cleaved by the
serine protease Factor D (FD) to generate Bb and Ba. Bb remains
bound to C3b while Ba is liberated (not shown). C3bBb is an active,
albeit transient, AP enzyme complex that cleaves C3 to form C3a
and C3b. C3a is a small peptide anaphylatoxin when released. C3b
covalently binds to a nearby target (T) surface forming an ester
linkage. Properdin binds to and stabilizes the C3bBb complex,
increasing the half-life 5-to 10fold. Thus, the cleavage of C3 to
C3b may result in a potent positive feedback amplification loop.
The AP C5 convertase (C3b)2 BbP (not shown) cleaves C5 to
C5a and C5b. C5a is a potent anaphylatoxin. C5b binds C6 and
C7 and C5b,6,7 complex attaches to a membrane. The binding
of C8 followed by multiple C9s then completes the formation of
the membrane attack complex (MAC), which has the capacity to
perturb cellular membranes including generating pores to lyse cells.
B, Crry mediates membrane cofactor activity in the mouse. After
Crry binds to C3b, then Factor I (FI), a plasma serine protease, can
now cleave C3b to iC3b. iC3b has no hemolytic potential because it
does not engage FB to initiate the feedback loop. Crry has intrinsic
complement regulatory activity in that it primarily acts on the same
cell on which it is expressed32
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routinely sacrificed at day 11.5 dpc. Implantation sites, including the

For trophoblast staining, 7.5 dpc implantation sites were collected

concepti and extraembryonic membrane surrounded by decidua,

as described above. Antigen retrieval was accomplished with 10 mmol/L

were weighed to confirm the dpc. Genotyping was performed on

Tris-EDTA pH 9.0 for 3 minutes in a pressure cooker. Staining was ac-

each litter. To accomplish this, the conceptus was removed, washed

complished with TROMA-I (1:50 dilution of hybridoma supernatant;

7× in cold PBS in a microtiter plate, and digested in proteinase K

Developmental Studies Hybridoma Bank, University of Iowa) and goat

(20 μg/mL) overnight at 55°C. DNA was precipitated, suspended in

anti-rat light chain horseradish peroxidase (HRP). Staining was visual-

10 mmol/L Tris, 0.1 mmol/L EDTA, and then analyzed by PCR as de-

ized with DAB. Controls employed a second Ab only.

scribed previously.15

2.3 | Transcardial perfusion

2.6 | FACS analysis of cells derived from 7.5 dpc
implantation sites

Mice were anesthetized with ketamine/xylazine (ketamine from

Implantation sites were harvested as described above. Each site was

Henry Schein, Dublin, OH; xylazine from Department of Comparative

cut into 12 pieces and placed in RPMI 5% fetal bovine serum (FBS).

Medicine, WUSM, St. Louis, MO). Transcardial perfusion with 50 mL

These pieces were digested in RPMI containing 5% FBS, 300 μg/

of Dulbecco’s phosphate-
buffered saline (DPBS; Sigma-
Aldrich,

mL collagenase F (Sigma-Aldrich), 200 μg/mL collagenase L (Sigma-

St. Louis, MO) containing 20 U/mL of heparin (Sigma-Aldrich) was

Aldrich), 500 μg/mL Dispase (Gibco), and 2 U/mL DNase-1 (Roche)

performed to remove plasma and red blood cells (RBCs) from the

at 37°C for 30-
45 minutes with a magnetic stir bar for agitation.

vasculature.

Cells were passed over a 70 μm strainer (BD) to create a single-
cell suspension. Implantation sites were washed in DPBS, 1% FBS,

2.4 | Frozen section histology

25 mmol/L EDTA. Cells were stained for FACS with anti-CD45 (30-
F11, BD), anti-CD11b (M1/70, BD), anti-Gr-1 (RB6-8C5, BD), and rab-

Implantation sites, harvested as above, were dehydrated in 20% su-

bit anti-Crry followed by a donkey anti-rabbit DyLight 488 (Jackson

crose overnight at 4°C, flash frozen in optimal cutting temperature

ImmunoResearch). Blocking for FACS was carried out employing

(Sakura USA, Torrance, CA) with 2-methylbutane, and cooled with

DPBS, 1% FBS, 25 mmol/L EDTA with 5% donkey serum, and 5%

dry ice. Cassettes were stored at −80°C. Frozen sections (7 μm)

mouse serum. Cells were examined employing a FACScan (BD) retro-

were prepared on a Leica CryoStat. For granulocyte-differentiation

fitted with a Cytek Upgrade.

antigen-
1 (Gr-
1) staining, frozen slides were fixed in pre-chilled
acetone at room temperature (RT). Endogenous peroxidase was
quenched with 0.3% H2O2 (Sigma-
Aldrich) in methanol (Fisher

2.7 | Cobra venom factor (CVF) treatment

Scientific, St. Louis, MO). Blocking was performed in PBS, 1% BSA,

Cobra venom factor (Quidel, A600) was administered intraperito-

5% mouse serum, and 5% goat serum. RB6-8C5 (BioXCell 3.5 mg/

neally (20 μg/mouse) with a 31G insulin syringe (Terumo). Depletion

mL, a rat monoclonal anti-mouse Gr-1 Ab) was used at a dilution of

of C3 occurs in <1 hour. C3 hemolytic and antigenic activity is un-

1:500 in the blocking buffer. Another anti-G r-1 Ab (1A8) was used

detectable for up to 3-4 days and then there is a gradual increase to

at 1:500 (BioXCell). The secondary Ab was a goat anti-rat light chain

normal levels over approximately a week. 21,22

horse radish peroxidase (HRP; Jackson Immunoresearch). Staining
was visualized with DAB (3, 3′-diaminobenzidine; Vector, IMPACT
DAB KIT).

2.8 | Neutrophil depletion
Neutrophils were depleted by intraperitoneal injection (IP) injec-

2.5 | Immunohistology

tion of RB6-8C5, a rat IgG2b mAb against Gr-1 (Ly6G/C). A 250 μg
dose of this Ab depleted neutrophils in the periphery for 5 days and

Implantation sites were fixed in 10% formalin overnight, embed-

a 500 μg dose depleted for 6 days. Both doses are followed by a re-

ded in paraffin, 8 μm sections were rehydrated, antigen retrieval

bound neutrophilia (approximately a doubling of pre-depletion lev-

was performed, non-specific binding was blocked, and specific im-

els), which we were unable to overcome with an additional IP dose

munostaining was conducted as described below. In the case of

4 days after the first dose. 1A8 is a second anti-Gr-1 rat IgG2a Ab

Crry staining, antigen retrieval was performed in 10 mmol/L citric

(BioXCell). A 500 μg dose of 1A8 depleted ~50% of the neutrophils

acid (anhydrous; Sigma-Aldrich), 0.05% Tween-10, pH 6.0 in a pres-

when the peripheral blood was assayed at 72 hours.

sure cooker for 3 minutes. Blocking and staining were performed in

In the initial experiments, we used RB6-8C5 that was a gift from

1% BSA, 10% donkey serum, and 5% mouse serum in PBS. Rabbit

Emil Unanue (Washington Univ. School of Medicine, Department

anti-Crry (1:1000; provided by V. Michael Holers, Division of

of Pathology and Immunology, St. Louis, MO). 23 RB6-8C5 was also

Rheumatology, University of Colorado School of Medicine, Aurora,

produced within the laboratory by hybridoma cells. The mAb was

CO) was placed in blocking buffer overnight. Donkey anti-rabbit

purified from supernatants on a protein G column and then dialyzed

HRP (Jackson Immunoresearch) was used at 1:200. Staining was

against PBS. RB6 was also purchased from BioXCell (West Lebanon,

visualized with diaminobenzidine (DAB).

NH).
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Treatment with CVF prior to 8.5 dpc rescues Crry−/− implantationsa
Resorbed implantations
(% of total)

Crry−/− implantations rescued

dpc of treatment
(litters)

Full size implantations
(fraction of total)

Resorbed implantations
(fraction of total)

3.5 (3)

26/27

1/27

4

Yes**

4.5 (2)

19/20

1/20

5

Yes**
Yes

5.5 (1)

10/10

0/10

0

6.5 (2)

13/15

2/15

13

Partial*

7.5 (3)

24/27

3/27

11

Partial**

8.5 (3)

17/25

8/25

32

No

CVF, cobra venom factor; dpc, day post-coitus.
Data derived from crosses between Crry+/− females and Crry+/− males. Approximately, 25% of the resulting concepti would be expected to be Crry−/−
and resorbed in the absence of CVF treatment. Implantation sites were evaluated and genotyped at 11.5 dpc.
**P < .01 and *P < .05 compared with the proportion of full size implantations if not treated. The 5.5 dpc had only 1 treated litter; a statistical test was
not performed. Partial rescue indicates the number of resorbed implantations was between a full rescue and no rescue.

a

dpc of treatment
(litters)

Crry−/− pupsb (fraction
of total)

Crry−/− pups (% of
total)

Crry

3.5 (3)

7/17

41

Yes***

−/−

4.5 (2)

10/16

63

Yes***

5.5 (5)

14/26

53

Yes***

pups rescued

TA B L E 2 Treatment with CVF enables
the birth of Crry−/− pupsa

CVF, cobra venom factor; dpc, day post-coitus.
a
Data derived from crosses between Crry+/− females and Crry−/− males. Approximately, 50% of the
concepti are expected to be Crry−/−. Pups were genotyped at birth. No Crry−/− pups were born when
CVF treatment was omitted (7 litters).
b
Crry−/− pups were normal in size and developed comparably to wild-t ype mice. The Crry−/− females
were fertile and delivered normal litters when crossed to Crry+/+ males.
***P ≤ .005 compared with the expected percentage (0%) of Crry−/− pups in the absence of CVF
treatment.

3 | R E S U LT S
3.1 | Timing of AP activity required for conceptus
loss and depletion of the AP by CVF

3.2 | Effects of depletion of properdin by
anti-properdin antibody
Properdin (P) is critical for AP activity in many systems as this posi-

Crry−/− products of conception are known to undergo demise

tive regulator stabilizes the C3 convertase 5-to 10 fold. 26-28 The

before 10.5 dpc with maternal AP components playing a critical

P −/− background rescues Crry−/− viability, 24 as does FB−/−,13 FD−/− (X.

We sought to determine when the lethal AP activity oc-

Wu and J.P. Atkinson, unpublished) and C3−/−.14 A treatment of newly

curred and we chose treatments that could suspend AP activity after

pregnant mice with a rabbit polyclonal Ab to mouse properdin also

implantation. CVF is a C3b analog that forms a stable AP convertase

restored Crry−/− viability (Table 3). 29

13-15,24

role.

with Bb (CVFBb), and unlike host AP C3 convertases, CVFBb is not

Treatment with a neutralizing anti-mouse properdin mAb also

susceptible to inhibitory activity of the complement regulators. 25

rescued Crry−/− concepti. 29 Specifically, treatment with 1 mg of the

Consequently, treatment with CVF rapidly depletes circulating C3

H4 hamster anti-mouse properdin mAb at 6.5 and 7.5 dpc resulted

and diminishes FB, fully exhausting complement activity. 22

in 32% Crry−/− pup viability, compared to the expected 0% without

We depleted AP by injecting 20 μg CVF IP into newly pregnant mice
and examined Western Blots of serum for C3. This approach yielded no

treatment (P = .0005, 25 pups, 4 litters) and the 50% viability expected from Crry+/− female × Crry−/− male.

detectable C3 for the next 4 days, with C3 levels returning to 50% of
normal by 7 days post-injection. The fetuses were genotyped and the
placenta examined at 11.5 dpc. CVF treatment administered between
−/−

3.5 and 5.5 dpc rescued Crry

3.3 | Histology of the implantation site

mice, compared to controls (Table 1).

The above results showed that conception loss was prevented if

Treatment at 6.5 or 7.5 dpc led to ~50% rescue. Of note, CVF treatment

AP inhibition began before 6.5 dpc, and a partial effect existed

had no adverse effect on pup survival, as Crry−/− pups were born to

if inhibition began by 6.5-7.5 dpc. The ectoplacental cone cells

CVF-treated mothers similar to controls (Table 2), matured as expected,

of the mouse are precursors to the labyrinthine trophoblast in

and Crry−/− females were fertile (not shown).

the placenta. The cone cells contact maternal RBCs as early as

|
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5.5 dpc and are bathed in blood at 6.5 dpc. 20 The yolk sac pla-

hypothesizing that deficiency of C3aR would rescue the Crry−/− em-

centa offers nutrition to the conceptus until 9.5 dpc, when the

bryos. The preceding cross was predicted to have 25% Crry−/− pups

labyrinthine placenta assumes the major role in maternal-f etal ex-

among the offspring, however, among the 59 viable pups, we ob-

change (Figure 2). Importantly, we observed that at 8.5 dpc there

served no Crry−/− pups, indicating that the absence of C3aR was not

was a substantial difference in the size of the allantoic vessels, a

sufficient to rescue Crry−/− concepti (Table 4).

lack of proliferation of the labyrinthine trophoblasts, and smaller
than control embryos in Crry−/− gestations (Figure 3). Moreover,
the Crry−/− implantations at 9.5 dpc failed to evolve like controls,
with an undeveloped labyrinth and unexpanded chorioallantoic

3.5 | Neutrophils are not required for Crry-/-
conceptus loss
In the APLS model of embryonic lethality,30 complement-mediated

vessels (Figure 4).

damage is dependent on neutrophils. We observed neutrophils surrounding Crry−/− implantation sites on 7.5 dpc, but the impact on

3.4 | Anaphylatoxin C3a and its receptor are not
required for Crry−/− conceptus loss

conception viability has not been established.13 We pursued this
issue and first confirmed, by both FACS and immunohistochemistry,

A role for C3a in conception loss has not been studied. We tested
−/−

whether C3a:C3aR signaling directed the demise of the Crry

that neutrophils surrounded Crry−/− and Crry+/− implantation sites

.

at 7.5 dpc (Figure 5). Notably, we observed no correlation between

C3a receptor has been shown to be important in experimental

genotype and the number of neutrophils present. Also, there was no

lupus nephritis.
TA B L E 3

29

We mated Crry

+/−

−/−

C3aR

× Crry

+/−

−/−

C3aR

mice

correlation between CD45+ as a marker of hematopoietic-derived

Transient inhibition of properdin rescues Crry−/− implantationsa

dpc of treatment (litters)

Full size implantations
(fraction of total)

Resorbed implantations
(fraction of total)

Resorbed implantations (% of
total)

Crry−/− implantations rescued

3.5 + 7.5 (2)b

15/17

2/17

12

Yes***

6.5 + 7.5 (3)b

20/24

4/24

17

Yes***

c

12/17

5/17

29

No**

14/29

15/29

52

No

6.5 + 7.5 (2)
7.5 (3)

dpc, day post-coitus.
Data derived from crosses between Crry+/− females and Crry−/− males. Approximately, 50% of the resulting concepti would be expected to be Crry−/−
and resorbed in the absence of anti-properdin treatment. Implantation sites were evaluated and genotyped at 11.5 dpc.
b
One milligram rabbit anti-properdin on both days.
c
Five hundred microgram rabbit anti-properdin on both days.
***P < .005 and **P < .05 compared with the proportion of full size implantations if not treated.
a

(A)

F I G U R E 2 Maternal blood bathes the
ectoplacental cone trophoblast at 7.5 dpc.
A, Maternal red blood cells (RBCs) bathe
the ectoplacental cone (epc). B, RBCs are
visible at both ends of the amnionic sac.
C, Among the epc are trophoblast cells
that immunostain (brown) for cytokeratin
8 (TROMA-I). D, Gross dissection of
7.5 dpc implantation site shows blood at
both ends. All panels are from a 7.5 dpc
litter, sacrificed without perfusion to
retain maternal blood. Histology is from
formalin-fixed, paraffin-embedded
sections. A,B, are hematoxylin and eosin
stained. C, Immunocytochemical staining
by HRP-conjugated anti-cytokeratin 8.
em, embryo; epc, ectoplacental cone; tgc,
trophoblast giant cell. All images are 200×

(C)

(B)

(D)

6 of 11
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(A)

(B)

F I G U R E 3 Crry−/− embryos die at 8.5 dpc due to a failure of the allantoic vessels to attach to the chorionic plate. According to the
Theiler classification,19 the allantois contacts the chorion between 7.5 and 8.75 dpc. A, The allantois of Crry+/− embryos attaches to the
ectoplacental cone at 8.5 dpc and expands the chorionic plate. Notably, Crry+/− trophoblast giant cells immunostain positive (brown) for Crry.
B, The allantois of Crry−/− embryos, however, does not attach properly to the ectoplacental cone at 8.5 dpc and the allantoic vessels and the
trophoblast fail to develop normally. Crry−/− trophoblast giant cells do not stain positive (brown) for the Crry protein. Areas of Crry positive
cells in the decidua are not of fetal origin but are maternal blood cells within maternal vessels. All sections are formalin-fixed paraffin-
embedded sections. a, allantois; av, allantoic vessels; cp, chorionic plate; d, decidua; em, embryo; tgc, trophoblast giant cell
(A)

(B)

(C)

l

l
l

av
a

av
a

em

em
(D)

(E)

(F)

tgc

l

tgc
em

av

F I G U R E 4 Embryos at 9.5 dpc fail to develop allantoic vessels and labyrinth. A, Crry+/+ embryo is fully developed at 9.5 dpc. Its allantois
has fused with the mesoderm overlaying the ectoplacental cone. Black bar delineates the labyrinth. B, The allantoic vessels (black bar) have
expanded and nucleated fetal red blood cells (RBCs) are visible passing within the vessels into the labyrinth where the trophoblast interfaces
with maternal RBCs without nuclei (200× of box in A). C, Crry+/+ embryo at 9.5 dpc (20×). D, Trophoblast giant cells strongly express Crry
(brown, rabbit anti-Crry) and separate the maternal decidua from the labyrinth. E, Crry−/− embryo at 9.5 dpc has failed to develop. F, The
Crry−/− trophoblast giant cells do not stain for Crry, the labyrinth has not developed and allantoic vessels have not expand at 9.5 dpc. av,
allantoic vessels; L, labyrinth; em, embryo; tgc, trophoblast giant cell
cells or CD11b+ Gr-1− cells in either Crry−/− or Crry+/− genotypes at

We next treated pregnant mice at 4.5 dpc with RB6-8C5, a mAb

7.5 dpc. Neutrophils were present at implantation sites of all tested

that depletes Gr-1 (Ly-6C/G) positive cells, the majority of which

strains.

are neutrophils, and we confirmed the absence of neutrophils at

|

TRIEBWASSER et al.

TA B L E 4 The C3aR−/− background does
not rescue Crry−/− pupsa

7 of 11

Crry+/+
C3aR−/−
pups
(fraction of
total)

Crry+/− C3aR−/−
pups (fraction of
total)

Crry−/− C3aR−/−
pups (% of total)

Total pups

Crry−/− pups rescued

16/59

43/59

0/59

59

None

C3aR−/−, C3a receptor knockout mouse; dpc, day post-coitus.
a
Data derived from crosses between Crry+/− C3aR−/− females and Crry+/− C3aR−/− males. Pups were
genotyped at birth. Approximately 25% of the concepti are expected to be Crry+/+, 50% Crry+/−, and
25% Crry−/−. Loss of all Crry−/− concepti leads to approximately 66% Crry+/− and 33% Crry+/+ concepti.
There was no statistical difference between what was observed with these crosses and 11 Crry+/−
C3aR+/+ × Crry+/− C3aR+/+ control litters (P > .05).

Crry–/–

Crry+/–

Crry

Crry

8.26%

14.6%
22.6%

(D)

9.67%

Crry +/–

Crry –/–

CD11b
2.57%

65.2%

6.90%

70.3%

Gr1

Gr1
(F)

(E)

CD45+ Crry + fracon of 7.5 dpc
embryo implantaon sites

Gr1+ CD11b + percent of CD45+ Crry+ cells

CD11b

(C)

(B)

CD45

CD45

(A)

10

10

10

10

5

Crry +/–

Crry–/–

CD11b+ Gr1– percent of CD45+ Crry + cells

4

3

2

0

0

10

2

10

3

Crry

10

4

10

5

Crry +/–

Crry –/–

F I G U R E 5 Neutrophils are present around all embryos. A, Crry−/− embryos (left panel) have 3 cell populations when stained with anti-
Crry and anti-CD45 Abs. Crry+CD45+ population (maternal hematopoietic-derived cells), Crry+CD45− population (maternal decidua-derived
cells), and Crry− CD45− population (embryo-and trophoblast-derived cells). Crry+/− embryos (right panel) lack the Crry− CD45− population;
the embryo and trophoblast-derived cells cluster with maternal decidua-derived cells. B, There is no trend towards different proportions of
hematopoietic derived (CD45+) cells around Crry+/− versus Crry−/− embryos. C, The Crry+ CD45+ population contains Gr-1+ CD11b+ positive
cells, neutrophils. D, There is no difference in the proportion of neutrophils dependent upon genotype. E, Staining control for anti-Crry.
Crry−/− splenocytes in red and Crry+/− in blue. F, There is no difference in the proportion of CD11b+ Gr-1− cells dependent upon genotype
(subset of Crry+ CD45+)
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the sites of implantation at 7.5 dpc (Figure 6). Examination of the

and carries cofactor activity.32 In plasma and on cellular debris, fac-

surviving concepti at 10.5 and 13.5 dpc (Table 5), along with ge-

tor H (FH) performs a similar role. Crry is able via CA to permanently

notyping of litters (Table 6), indicated that neutrophil depletion

stop AP activation on cell membranes.33 In the Crry−/− mouse model,

by RB6-
8C5 did not improve Crry

−/−

viability. Similarly, deple-

excessive AP activation leads to conceptus demise by 8.5 dpc of de-

tion of neutrophils by treatment of pregnant mice with an anti-

velopment, highlighting the critical role played by regulators of the

Ly6G-specific Ab (1A8, 500 μg/mouse) had no detectable effect

AP. Crry−/− pups can be rescued by down modulating the levels of the

(Table 6). We concluded that neutrophils are not essential for loss
of the Crry

−/−

embryos.

AP activating proteins in the mother.15
The data herein show that transient depletion of the AP, either
with CVF or an anti-properdin Ab, is sufficient to rescue Crry−/− concepti. There is a critical window at 6.5-7.5 dpc when AP activation

4 | D I S CU S S I O N

leads to conceptus loss. In the case of CVF, treatment prior to this
window produces full rescue, but treatment during this 24-hour

The AP of the complement system is a constant sentinel, activating
15,31

continuously on surfaces and in the fluid phase.

Regulators on

period rescues about one-half of the concepti. Interestingly, if CVF
is given at 3.5 dpc prior to implantation of the blastocyst into the

cell membranes and in plasma are essential to control the level of

decidua, maternal C3 levels rise to ~50% by 7.5 dpc (4 d after CVF

activation. Crry is widely expressed on the surface of mouse cells

treatment) but Crry−/− embryos survive. This replicates the finding

(A)

(B)

(C)

(D)

(E)

(F)

(G)

(H)

(I)

F I G U R E 6 Neutrophils are present around 7.5 dpc embryos and RB6-8C5 depletes them from around embryos. A, Neutrophils are
present around the embryo at 7.5 dpc (anti-Gr-1 staining; 200×). B, This staining is specific for Gr-1+ and is not present in the isotype control.
C, At higher magnification (400×), the nuclear pattern characteristic of neutrophils can be seen inside of Gr-1+ cells. D,E, Identical patterns
are observed in staining for Gr-1+ (RB6-8C5, D) and Ly6G (1A8, E). F, Ly6G staining is specific to 1A8 and not seen in the isotype control. G-I,
Neutrophil depletion with 500 μg RB6-8C5 at 4.5 dpc leads to absence of neutrophils in the tissue at 7.5 dpc of Gr-1+ (G) and Ly6G+ cells
(H,I). em, embryo; epc, ectoplacental cone
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TA B L E 5

9 of 11

Neutrophil depletion does not rescue Crry−/− implantations

Female × male

dpc of treatmenta
(litters)

Crry+/− × Crry+/− (25%
Crry−/− expected)

RB6/5.5 (3)

19/27

8/27

30

No

RB6/6.5 (2)

13/17

4/17

24

No

PBS/6.5 (3)

17/25

8/25

32

No

RB6/4.5 (2)

6/14

8/14

57

No

Crry+/− × Crry−/− (50%
Crry−/− expected)

Full size implantations
(fraction of total)

Resorbed implantations
(fraction of total)

Resorbed implantations (% of total)

Crry−/− implantations rescuedb

RB6/4.5, 6.5 (2)

9/15

6/15

40

No

1A8/5.5 (3)

13/21

8/21

46

No

PBS, phosphate-buffered saline; dpc, day post-coitus.
a
RB6-8C5 (mAb anti-Gr1) 250 μg IP in Crry+/− × Crry+/− matings and 500 μg IP in Crry+/− × Crry−/− matings. 1A8 (mAb anti-Ly6G) 500 μg IP. Two dates
listed for dpc indicates that the dose was given twice.
b
No treatment condition significantly differed from the expected rate of resorptions (P > .05). Implantation sites were examined and genotyped at
11.5 dpc.

TA B L E 6

Neutrophil depletion does not rescue Crry−/− pupsa

dpc of
treatmentb

Crry+/− pups
(fraction of total)

Crry−/− pups
(fraction of total)

Crry−/−
pups
rescued

RB6/3.5

6/6

0/6

No

1A8/4.5

4/4

0/4

No

1A8/5.5

4/4

0/4

No

designed to identify the early events that contribute to the pathogenesis in this system. Previous work employing knockout mice
showed that fetal loss requires maternal AP components FB, FD,
properdin, and C3, that is, all 4 components of the AP. Here, we
extend these studies to demonstrate that depletion of maternal AP
components by 6.5 dpc, utilizing CVF treatment or neutralization of
properdin with an Ab, rescues the Crry−/− embryo. Within the inher-

dpc, day post-coitus.
a
Data derived from crosses between Crry+/− females and Crry−/− males (1
litter at each dpc of treatment). Approximately, 50% of the resulting concepti would be expected to be Crry−/−. Pups were genotyped at birth.
b
RB6-8C5 (mAb anti-Gr1), 500 μg IP; 1A8 (mAb anti-Ly6G), 500 μg IP.

ent 0.5 dpc in the Theiler staging system, the ~6.5 dpc critical time
period is when extraembryonic ectoplacental cone cells become
bathed in maternal blood and, consequently, immersed in maternal complement. 20 Wild-type components of the developing labyrinthine placentas connect to the maternal vasculature by 8.5 dpc
(Figures 2 and 3), and by 9.5 dpc the labyrinthine hemochorial placenta replaces the yolk sac placenta to assume the major duty of

that full blockade of the AP is not required for embryo survival, as

supplying nutrients to the fetus. In the Crry−/− embryo, the fusion of

haploinsufficiency of AP activating components will also rescue the

the allantois to the chorion during labyrinthine assembly does not

concepti.15

occur because the chorionic plate fails to develop and the labyrinthine trophoblast does not mature to be permeated by allantoic fetal
vessels (Figures 2 and 3).

4.1 | Timing of C3 deposition

Previous investigations of placental maldevelopment in the

C3 deposition on the ectoplacental cone of the Crry−/− mouse occurs

Crry−/− model have ruled out involvement of Ab,14 major contribu-

at approximately 7.5 dpc.13,14 We propose this takes place because

tions of C4 and C6.13-15,19 We now show there is no role for neu-

there is no membrane-based complement inhibitor on these cells.

trophils. Notably, maternal C5 deficiency has a limited restorative

Decay-accelerating factor (DAF), a GPI-anchored regulator, is not

effect, suggesting a minor role for C5a.13-15,19 Thus, the Crry−/−

13

expressed in the labyrinthine placenta until after ~10.5 dpc.

Other

model studies confirm a cause and effect relationship between

C3 regulators of complement such as FH are present in maternal

complement regulatory deficiency leading to excess AP activity and

blood but they are unable to compensate for Crry deficiency. For

aberrant placental development. Importantly, other mouse models

example, FH is normal in Crry−/− mouse but this complement regu-

demonstrate that placental insufficiency can occur through differ-

lator is insufficient to limit the diffuse AP activation observed on

ent complement-dependent scenarios: in the APS model, human au-

cells in the Crry−/− mouse.15 We surmise that the underlying cause

toantibodies bind autoantigens in the mouse placenta where they

of conceptus loss in this model is a dysregulated AP of complement

activate complement34 while in the abortion-prone mating combi-

activation on cell membranes.

nation of CBA/J female × DBA/2 male complement is activated via
the lectin pathway.35

4.2 | Mechanism of loss

The strengths of our study include the approaches that allowed
us to identify that a deficiency of maternal C3aR or a lack of neu-

In the Crry−/− mouse model, conceptus lethality is the result of in-

trophils does not prevent conceptus loss. A weakness is that we can

sufficient complement regulatory capacity. The current study was

only speculate that C3 deposition begins based on when maternal
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blood is apparent and when complete rescue of Crry−/− concepti
occurred in our CVF experiments. Our studies combined with the
above discussion suggest that the detrimental effects of AP activity
on the development of extraembryonic cells destined to form the
labyrinthine placenta are mediated primarily by C3b and/or its derivatives. We have previously extensively assessed the timing of C3b
deposition on placental tissue in the normal and complement regulatory protein (Crry) deficient mice.14,15

4.3 | Could dysregulation of the AP of complement
yield some forms of the preeclamptic phenotype?
Preeclampsia (PE) is a syndrome that associates with placental maldevelopment in the first trimester, yielding placental dysfunction in
the second half of pregnancy.36,37 The placenta is deemed a root
cause for many of the variable phenotypes of PE and immune-based
maternal-fetal incompatibilities contribute to some forms of the PE
syndrome.38 Notably, patients with this syndrome show greater systemic complement AP activity compared to normotensive women,
but debate persists as to a cause-effect relationship of this finding with the pathogenesis of the disorder. We recently presented
studies of cohorts of autoimmune and non-autoimmune PE patients
that demonstrate an association of PE with dysfunctional complement regulatory genes, including FI, FH, and MCP.39,40 These findings suggest that some cases of PE may be initiated by insufficient
regulatory capacity and excessive AP complement activity during
development, predisposing the placenta to maldevelopment, injury,
or both during gestation. Further investigation is needed to determine the scope of excessive complement activity in human placental
dysfunction.
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